Tumor antigen protein SART-3 and tumor antigen peptides thereof

Details Tumor antigen protein SART-3 and tumor antigen peptides thereof Tumor antigen protein SART-3 and tumor antigen peptides thereof

2011-06-28

2011-06-28

Yu, Misook (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S333000, C424S277100

Reexamination Certificate

active

07968676

ABSTRACT:
A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided.

REFERENCES:
patent: 5750395 (1998-05-01), Fikes et al.
patent: 2006/0035251 (2006-02-01), Young et al.
patent: 0911397 (1999-04-01), None
patent: 1033401 (2000-09-01), None
patent: WO-97/46676 (1997-12-01), None
patent: WO-00/55174 (2000-09-01), None
Toh et al., Cellular Immunology, vol. 177, Article No. CI971105, pp. 137-143, (1997).
Yang et al., Cancer Research, vol. 59, pp. 4056-4063, (1999).
Accession No. HSORF51, “Human mRNA for KIA0156 gene, complete cds.”, Aug. 8, 1995, EMBL Database.
Accession No. AAGO1853, “Human Secreted protein, SEQ ID No: 5934.”, Sep. 6, 2000, EMBL Database.
Shuchijo et al., “A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T lymphocytes” J. Exp. Med, vol. 187, No. 3, pp. 277-288, (Feb. 2, 1998).
Gohara “Histocompatibility Leukocyte Antigen-A2402-restricted Cytotoxic T Lymphoctyes Recognizing Adenocarinoma in Tumor-infiltrating Lymphocytes of Patients with Colon Cancer” Jpn. J. Cancer Res., vol. 88, No. 2, pp. 198-204, (Feb. 1997).
Nagase “Prediction of the Coding sequences of Unidentified Human Genes. IV. The Coding Sequence of 40 New Genes (KIAA0121-KIAA0160) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1” J. Clin. Invest., vol. 2, No. 4, pp. 167-174 (Aug. 1995).
Yotnda “Cytotixic T cell Response Against the Chimeric ETV6-AML1 Protein in Childhood Acute Lymphblastic Leukemia” J. Clin. Invest., vol. 102, No. 2, pp. 455-462, (Jul. 1998).
Takahashi “Recognition of gp43 Tumor-Associated Antigen Peptide by both HLA-A2 Restricted CTL Lines and Antibodies from Melanoma Patients” Cellular Immunology, Col. 178, No. 2, pp. 162-171, (Jun. 15, 1997).
Rosenberg et al., “Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2” ; J. of the Natl. Cancer Inst., vol. 86, No. 15, (Aug. 1994).
Rammensee et al., “MHC Ligands and Peptide Motifis: First Listing”; Immunogenetics, vol. 41, pp. 178-228 (1995).
Kubo et al., “Definition of Specific Peptide Motifs for Four Major HLA-A Alleles” ; J. Of Immunology, vol. 152, pp. 3913-3924 (1994).
Kondo et al., “Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules” ; J. of Immunology, vol. 155, pp. 4307-4312 (1995).
Sudo et al., “Differences in MHC Class I Self peptide Repertoires among HLA-A2 Subtypes” ; The J. of Immunology, vol. 155, pp. 4749-4756 (1995).
Rivoltini et al., “Induction of Tumor-Reactive CTL from peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART-1”; The J. of Immunology, vol. 154, pp. 2257-2265 (1995).
Kharkevitch et al., “Characterization of Autologous Tumor-Specific T-Helper 2 Cells in Tumor-Infiltrating Lymphoctyes from a Patient with Metastatic Melanoma” ; Int. J. Cancer, Col. 58, pp. 317-323 (1994).
Van Tsai et al. “Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells” ; The J. of Immunology, vol. 158, pp. 1796-1802 (1997).
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes” ; Science, Col. 274, pp. 94-96 (Oct. 1996).
Nakao et al., “HLA A2601-restricted CTLs Recognize a peptide Antigen Expressed on Squamous Cell Carcinoma” ; Cancer Research, Col. 55, pp. 4248-4252 (Oct. 1995).
Thompsen et al., “Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination” ; The J. of Immunology, Col. 160, pp. 1717-1723 (1998).
KIAA0156 (Genbank Accession No. D63879), (Jul. 10, 1997).
HLA-A2 cDNA (Genbank Accession No. M84379), (Jan. 7, 1995).
Crystal, R.G. Science. vol. 270, pp. 404-410, (Oct. 1995).
Tait et al., Clin. Canc. Res., vol. 5, pp. 1708-1714, (Jul. 1999).
Gura, Science, vol. 278, pp. 1041-1042, (1997).
Miyagi et al., Clinical Cancer Res., vol. 7, pp. 3950-3962, (2001).
Kurshid et al., Analytical Biochemistry, vol. 208, pp. 138, (1993) Abstract.
Gaiger et al., Blood, vol. 96, pp. 1480-1489, (2000).
Boon, Adv. Can. Res., vol. 58, pp. 177-210, (1992).
Spitler, Cancer Biotherapy, vol. 10, pp. 1-3, (1996).
Ezzel. J. NIH Res., vol. 7, pp. 46-49, (1995).
Nagase et al., DNA Res., vol. 2, pp. 167-174, supplement 199-210, (1995).
Campbell, Monoclonal antibody technology, Elsevier Science Publishers, Chapter 1, pp. 1-32.
Sambrook et al., Molecular Cloning, A Laboratory Manual, Chapters 3 and 12 (1989).
Kausch et al., Plan Physiol, vol. 107 pp. 669-670, 1995.
SEQ ID N:3 search variant.
Sequence search result.
Yang et al., Cancer Research. vol. 59, pp. 4056-1063, 1999.
Abbas et al., Cellular and Molecular Immunology, 4th edition. 2000, p. 71-72.
Uniprot-7.2 database, Accession No. Q15020.
Nagase et al., DNA Res, 2:167-174, 1995.
Official Action issued in JP2000-567688.

Affiliated with

Also associated with

Rating

Tumor antigen protein SART-3 and tumor antigen peptides thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor antigen protein SART-3 and tumor antigen peptides thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen protein SART-3 and tumor antigen peptides thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2729296